Purpose of the Test
- Evaluate the effectiveness of chemotherapy or radiation.
- Early detection of potential disease relapse.
- Determine the need for adjusting the treatment protocol.
Book MRD Testing for Myeloma | Lahalak Medical Platform
MRD testing is a vital tool for assessing treatment response in myeloma patients. It detects microscopic cancer cells invisible to standard tests, helping clinicians personalize treatment plans and effectively prevent potential relapses.
Scientific name: Minimal Residual Disease (MRD) Testing
An advanced test using flow cytometry or NGS to detect residual cancer cells after chemotherapy or marrow transplant, ensuring long-term remission and guiding clinical decisions.
Service type
Specialized Laboratory Test
Duration
30-60 minutes
Fasting
Fasting is not required
Included Services
- Sample collection (Blood or Marrow)
- Flow Cytometry/NGS analysis
- Detailed medical result report
Medical Service Information
Target Groups
- Patients with Multiple Myeloma.
- Leukemia patients post-treatment.
- Patients undergoing bone marrow transplantation.
Why Choose MRD Testing?
- Extreme sensitivity, detecting up to one cell in a million.
- Significantly higher accuracy than traditional microscopic tests.
- Empowers doctors to make critical decisions regarding treatment duration.
Conditions & Notices
- Requires prior coordination with an oncologist
- May require a bone marrow biopsy based on clinical status
Medical services you might also like
